LIVE

AGGREGATED External reporting by Bloomberg. This page summarizes the publisher's feed entry; the full article is on www.bloomberg.com.

Fresenius Taps China’s WuXi to Expand Biosimilar Drug Portfolio

BLOOMBERG · Sonja Wind ·

Fresenius SE agreed to partner with Chinese contract drug developer WuXi Biologics on biosimilar candidates that could reach the market in the next decade, potentially more than doubling its current portfolio.

READ THE ORIGINAL AT BLOOMBERG ↗ MORE FROM THIS SOURCE

RELATED REPORTING